Recombinant interferon-α2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: Final analysis of CALGB 8691

Leukemia and Lymphoma

Volumn 50, Issue 10, 2009, Pages 1606-1617

  Smith, S M ^a   Johnson, J ^b   Cheson, B D ^c   Canellos, G ^d   Petroni, G ^b   Oken, M ^e   Duggan, D ^f   Hurd, D ^g   Gockerman, J P ^c   Parker, B ^h   Prchal, J ⁱ   Peterson, B A ^j  

^a UNIVERSITY OF CHICAGO   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c DUKE UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Eastern Cooperative Oncology Group   (United States)

^f SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^g WAKE FOREST UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

^j UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

Cyclophosphamide; Follicular lymphoma; Interferon; Maintenance

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT ALPHA2B INTERFERON; ALKYLATING AGENT; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; IMMUNOLOGIC FACTOR;

ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; BODY WEIGHT; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG SAFETY; EDEMA; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; GOUT; GRANULOCYTOPENIA; HODGKIN DISEASE; HOT FLUSH; HUMAN; INFECTION; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; NIGHT SWEAT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SECOND CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG POTENTIATION; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SURVIVAL; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2B; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; SURVIVAL ANALYSIS; TREATMENT FAILURE; YOUNG ADULT;

EID: 70350757828     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903093807     Document Type: Article

References (21)

1. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged singleagent versus combination chemotherapy in indolent follicular lymphomas: A study of the cancer and leukemia group B. J Clin Oncol 2003;21:5-15.
2. Foon KA, Sherwin SA, Abrams PG, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984;311:1148-1152.
3. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007;282:20047-20051.
4. Vilcek J. Fifty years of interferon research: Aiming at a moving target. Immunity 2006;25:343-348.
5. Wadler S, Schwartz EL. New advances in interferon therapy of cancer. Oncologist 1997;2:254-267.
6. Ozer H, Anderson JR, Peterson BA, et al. Combination trial of subcutaneous recombinant a-2b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma. Med Pediatr Oncol 1994;22:228-235.
7. Peterson B, Petroni GR, Oken MM, Johnson JL, Barcos M, Cooper MR. Cyclophosphamide versus cyclophosphamide plus interferon a-2b in follicular low grade lymphomas: An intergroup phase III trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 1997;16.
8. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics 1979;35:183-197.
9. Pocock SJ. Clinical trials: A practical approach. New York: Wiley; 1983.
10. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974;27:365-375.
11. Andersen JW, Smalley RV. Interferon a plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up. N Engl J Med 1993;329:1821-1822.
12. Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon a-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998;16:41-47.
13. McLaughlin P, Cabanillas F, Hagemeister FB, et al. CHOPBleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 1993;4:205-211.
14. Smalley RV, Andersen JW, Hawkins MJ, et al. Interferon a combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992;327:1336-1341.
15. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicincontaining regimen with or without interferon a-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998;16:2332-2338.
16. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215-2223.
17. Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-a-2a. Clin Cancer Res 2000;6:2644-2652.
18. Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-a 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001;86:951-958.
19. Kimby E, Jurlander J, Geisler C, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon a-2a: A randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008;49:102-112.
20. Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350-5357.
21. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells. N Engl J Med 2004;351:2159-2169.